Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Biosplice Therapeutics, Inc.
🇺🇸
United States
Country
🇺🇸
United States
Ownership
Holding
Employees
51
Market Cap
-
Website
http://www.biosplice.com
Clinical Trials
Related News
Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
Phase 1
Completed
Conditions
Hepatic Cancer
Gastric Cancer
Colorectal Cancer
Pancreatic Cancer
Interventions
Drug: SM04755
Subscribe
First Posted Date
2014-07-16
Last Posted Date
2018-09-07
Lead Sponsor
Biosplice Therapeutics, Inc.
Target Recruit Count
13
Registration Number
NCT02191761
Subscribe
Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)
Phase 1
Completed
Conditions
Moderate to Severe Osteoarthritis
Interventions
Drug: SM04690, 0.23mg/2mL
Drug: SM04690, 0.03mg/2mL
Drug: SM04690, 0.07mg/2mL
Drug: Placebo
Subscribe
First Posted Date
2014-03-26
Last Posted Date
2015-12-10
Lead Sponsor
Biosplice Therapeutics, Inc.
Target Recruit Count
61
Registration Number
NCT02095548
Subscribe
Prev
1
2
3
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy